Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 19, 2010

Primary Completion Date

November 29, 2012

Study Completion Date

December 18, 2012

Conditions
Peripheral Artery Disease
Interventions
DRUG

Cilostazol, Probucol

"Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID"

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

All Listed Sponsors
lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY